Fierce Healthcare and Fierce MedTech's 17 rising stars in health tech ADA: With promising long-term data for its artificial pancreas, Medtronic aims to fully close the diabetes management loop ASCO: AstraZeneca, Daiichi’s Enhertu could transform breast cancer treatment with landmark HER2-low show ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner? ASCO: HER2 diagnostics need a revolution as AstraZeneca, Daiichi’s Enhertu looks to redefine breast cancer With Vascepa sales tanking, Amarin cuts US headcount by 65%, replaces CFO Healthcare access looms as doctors' top concern, followed by substance abuse, racial disparities and gun control Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech BD to enter pharmacy automation market with $1.5B Parata purchase Pfizer makes $120M domestic manufacturing play to shore up COVID antiviral supply Bain Capital scoops up LeanTaaS, makes significant investment to fuel growth of healthcare AI Biogen bets more than $700M on Alectos' preclinical oral Parkinson's drug to shore up pipeline ADA: Insulet sets up wide-scale rollout of Omnipod 5 insulin pump Prime's IntegratedRx pilot drives $1.1M in specialty pharmacy waste reduction Featured Story | By Conor Hale,Heather Landi Fierce Healthcare and Fierce Medtech compiled a list highlighting some of the biggest rising stars in the health tech industry, spanning the fields of artificial intelligence, software development and health IT. read more |
| |
|---|
|
Top Stories By Andrea Park In an interview with Fierce Medtech during the ADA's scientific sessions, the chief medical officer of Medtronic’s diabetes business, Robert Vigersky, described how the company is looking to completely close the loop on insulin delivery. read more By Angus Liu A new era of breast cancer treatment may be upon us. With a landmark clinical trial win, AstraZeneca and Daiichi Sankyo could soon open up a brand-new breast cancer category and offer HER2-targeted therapy for many patients with what’s been traditionally characterized as HER2-negative disease. read more By Gabrielle Masson The numbers as they stand now don’t lie: Amgen’s Lumakras lasted longer than Mirati’s adagrasib in KRAS-mutated lung cancer. But Mirati's CEO still has high hopes for adagrasib, as an investigator of a study into the latecomer drug told Fierce Biotech that the two therapies have shown "essentially identical" efficacy. read more By Annalee Armstrong Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for commercialization? read more By Angus Liu With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing how the HER2 biomarker should be measured by diagnostic tests. read more By Kevin Dunleavy Amarin is signaling defeat in its attempts to keep its heart-helping drug Vascepa viable against generic competition in the United States. On Monday, the Dublin-based company revealed it will slash its workforce in the U.S. by 65% in a restructuring plan. read more By Susan Kreimer U.S. physicians rank healthcare access, substance abuse and racial disparities as the leading social issues facing the country, followed closely by gun control and climate change, according to a new survey read more By Nick Paul Taylor Yumanity Therapeutics has struck two agreements to erase itself from existence. Johnson & Johnson has stepped in to take on Yumanity’s lead program and unpartnered discovery-stage candidates, while Kineta has laid claim to its Nasdaq listing and Merck collaboration through a reverse merger. read more By Conor Hale The big medtech signed up to buy Parata Systems from its corporate owner Frazier Healthcare Partners through an all-cash deal expected to close before next March. read more By Fraiser Kansteiner Pfizer on Monday said it’s plugging $120 million into its Kalamazoo, Michigan, plant—the Big Pharma’s largest manufacturing facility—to bolster production of its oral COVID-19 antiviral Paxlovid, also known as nirmatrelvir and ritonavir tablets. read more By Heather Landi Private equity firm Bain Capital snapped up software company LeanTaaS to gain a foothold in the healthcare AI and automation space. The deal also included a "significant" capital investment to help fuel the company's growth. read more By Max Bayer Biogen is looking to fortify the back end of its pipeline, betting more than $700 million on Alectos' preclinical oral Parkinson's med. The two companies will partner on the development of the asset until it's ready for the clinic, at which point Biogen will take the reins. read more By Andrea Park 2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump, and the company has spent the ensuing months building out the system’s platform and making it available to more users than ever before. read more By Paige Minemyer Specialty pharmacy is a huge cost concern in the industry, and a new study suggests that using a medically-integrated dispensing model could yield significant savings. read more |
